Cite
El-Shabrawi MH, Sherief LM, Yakoot M, et al. Effects of dual sofosbuvir/daclatasvir therapy on, chronic hepatitis C infected, survivors of childhood malignancy. World J Clin Cases. 2019;7(16):2247-2255doi: 10.12998/wjcc.v7.i16.2247.
El-Shabrawi, M. H., Sherief, L. M., Yakoot, M., Kamal, N. M., Almalky, M. A., AbdElgawad, M. M., Mahfouz, A. A., Helmy, S., Kamal, E. M., Attia, D., & El-Khayat, H. R. (2019). Effects of dual sofosbuvir/daclatasvir therapy on, chronic hepatitis C infected, survivors of childhood malignancy. World journal of clinical cases, 7(16), 2247-2255. https://doi.org/10.12998/wjcc.v7.i16.2247
El-Shabrawi, Mortada Hf, et al. "Effects of dual sofosbuvir/daclatasvir therapy on, chronic hepatitis C infected, survivors of childhood malignancy." World journal of clinical cases vol. 7,16 (2019): 2247-2255. doi: https://doi.org/10.12998/wjcc.v7.i16.2247
El-Shabrawi MH, Sherief LM, Yakoot M, Kamal NM, Almalky MA, AbdElgawad MM, Mahfouz AA, Helmy S, Kamal EM, Attia D, El-Khayat HR. Effects of dual sofosbuvir/daclatasvir therapy on, chronic hepatitis C infected, survivors of childhood malignancy. World J Clin Cases. 2019 Aug 26;7(16):2247-2255. doi: 10.12998/wjcc.v7.i16.2247. PMID: 31531319; PMCID: PMC6718790.
Copy
Download .nbib